ATTACHMENT – C: Survey Instrument
Evaluation of the CDC Molecular Detection of Drug Resistance Testing Service for isolates of Mycobacterium tuberculosis complex (Pilot Survey Version 1, 10/19/2011)
How did you first get information on the MDDR testing service offered by CDC?
CDC website
“Dear Colleague” letter
Conference call with CDC
Professional meeting
Regional Training and Medical Consultation Center (RTMCC)
TB control program
Another public health laboratory
CDC TB Laboratory Consultant
Who initiates requests for the molecular detection of drug resistance (MDDR) testing at CDC? (Check all that apply.)
Health care provider
TB control program
Laboratory
Laboratory only after consultation with program staff
Other. Please explain: ________________________________________________
Were you satisfied with the turnaround time for receiving results from the MDDR testing service?
Very satisfied
Satisfied
Neither satisfied nor dissatisfied
Dissatisfied
Very dissatisfied
What is the usual timeframe for your laboratory to report interim molecular results from the MDDR service to health care providers?
Molecular results are reported directly to health care provider within 1 business day of receipt from CDC
Molecular results are reported directly to health care provider within 2 business days of receipt from CDC
Reporting time to health care provider varies depending on circumstances
Molecular results are reported to health care provider by TB Control Program
Not applicable. Health care provider receives separate MDDR report from CDC
In general, does your laboratory withhold reporting molecular results from the MDDR service until conventional drug susceptibility testing is completed by CDC?
Yes. Please state why molecular results are withheld:
___________________________________________________________________________
Sometimes. Please state why molecular results are sometimes withheld:
___________________________________________________________________________
No, molecular results are reported as soon as possible
Not applicable. Molecular results are reported to health care provider by TB Control Program
Not applicable. Health care provider receives separate report from CDC
In general, does your laboratory withhold reporting molecular results from the CDC MDDR service until conventional drug susceptibility testing is completed by your laboratory?
Yes. Please state why molecular results are withheld
________________________________________________________________________
Sometimes. Please state why molecular results are sometimes withheld:
_________________________________________________________________________
No, molecular results are reported as soon as possible
Not applicable. Molecular results are reported to health care provider by TB Control Program
Not applicable. Health care provider receives separate report from CDC
How are results from the CDC MDDR service reported?(Check all that apply)
Verbally
Copy of CDC report is provided
CDC results are transcribed into LIMS for reporting
Not applicable. CDC results are not reported by our laboratory
Does your laboratory compare molecular results from the CDC MDDR service with your local test results for conventional drug susceptibility with first-line drugs?
Yes, we always compare molecular results from CDC with our local test results (Skip to question 10)
Sometimes we compare molecular results from CDC with our local test results (Skip to question 10)
No, we report the molecular results from CDC without comparing to our local test results
Not applicable. We do not perform first-line drug susceptibility testing
If you indicated that you do not compare molecular results from CDC with local testing, please indicate the reason (Check all that apply).
Our laboratory is not fully qualified to compare molecular results from CDC with our local results
We report molecular results from CDC and results from local testing without further comparison and interpretation
We only compare conventional drug susceptibility test results from CDC with our local testing.
Other. Please explain ____________________________________
(AFTER ANSWERING QUESTION #9, PLEASE SKIP TO #12.)
If you indicated that you do compare molecular results from CDC with your local testing results for first-line drugs, please indicate the reason. (Check all that apply)
Results are compared for quality assurance purposes
Results are compared for increasing understanding of molecular testing
Results are compared to find discordance
Results are compared in preparation for consultation with the health care provider or TB Control Program if needed
Other. Please explain ___________________________________
If you indicated that you do compare molecular results from CDC with your own local testing results for first-line drugs, have you ever found potential discordance (i.e., mutation detected indicating potential resistance to rifampin but conventional local drug susceptibility test result was rifampin susceptible)?
Yes, we found potential discordance between the CDC molecular result and the conventional local drug susceptibility test result
No, we have not found any potentially discordant results (Skip to question 13)
If you found discordance between the molecular results from CDC and local test results for conventional drug susceptibility what additional actions, if any, were initiated by your laboratory? (Check all that apply.)
No additional actions were taken.
Contacted the Division of Tuberculosis Elimination Laboratory Branch at CDC to discuss results
Retested isolate in our laboratory
Withheld sending CDC results to health care provider or TB Control
Contacted TB Control Program to notify them of potential discordance
Initiated a corrective action plan in our laboratory
Referred an isolate from the patient to another laboratory other than CDC for molecular testing
Referred an isolate from the patient to another laboratory other than CDC for conventional drug susceptibility testing
Additional action taken by our laboratory depends on what drug is indicated as having the potential discordance (i.e., contact CDC about potential discordant result for rifampin but not for isoniazid)
Please provide any additional information for this response: ___________________________________________________________________________________________________________________________________________________________________________________________
Do you compare molecular results from CDC for potential discordance with second-line drug susceptibility test results obtained from local testing?
Yes, always
Yes, sometimes. Please explain: ___________________________________
No, we do not perform second-line drug susceptibility testing
No, we perform conventional second-line drug susceptibility testing but do not compare with molecular results from CDC
If the molecular results from the MDDR service are the first results available regarding susceptibility of an isolate, how do these results impact conventional drug susceptibility testing performed locally?
Results have no impact on local testing
Local results are disregarded
If resistance is indicated by molecular results, isolate is referred to another laboratory other than CDC for additional testing
Other. Please explain: ______________________________________________
Have you observed, as indicated on the CDC final report, potential discordance between the preliminary molecular results and the phenotypic test results reported by CDC? (In answering this question, only consider results from CDC and not local testing.)
Yes, we have observed discordance
No, we have not observed discordance (Skip to question 17)
No, we do not examine CDC results for discordance (Skip to question 17)
If you observed potential discordance between the preliminary molecular and final phenotypic test results reported by CDC, what additional actions, if any, were initiated by your laboratory? (In answering this question, only consider results from CDC and not local test results) (Check all that apply.)
No additional actions were taken
Contacted the Division of Tuberculosis Laboratory Branch at CDC to discuss results
Retested isolate in our laboratory
Withheld sending CDC results to health care provider or TB Control
Contacted TB Control Program to notify them of potential discordance
Referred an isolate from the patient to another laboratory other than CDC for molecular testing
Referred an isolate from the patient to another laboratory other than CDC for conventional drug susceptibility testing
Additional action taken by our laboratory depends on what drug is indicated as having the potential discordance (i.e., contact CDC about potential discordant result for rifampin but not for isoniazid)
Please provide any additional information regarding action depends on the specific antituberculosis drug indicated: ____________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________
Did you have any difficulty interpreting the molecular results from the MDDR service as provided on the report form?
The results were very difficult to interpret
The results were somewhat difficult to interpret
The results were not difficult to interpret
The results were very easy to interpret
Were you comfortable discussing interpretation of the molecular results from the MDDR service with health care providers or TB control?
Very comfortable discussing the results
Had some difficulty explaining the results
In most instances, not contacted for help interpreting the results
If you experienced any difficulty interpreting the molecular results from the MDDR service, where did you seek help? (Check all that apply.)
Contacted CDC TB Laboratory for help interpreting the report
Visited the CDC website for more information on the MDDR testing service
Consulted with other laboratory experts to interpret results
Consulted with clinician for help in interpreting results
Did my own research to find information on interpretation
Contacted local TB program in consultation for interpreting the results
Contacted RTMCC in consultation for interpreting the results
I did not seek additional help for interpreting the results
Public reporting burden of this collection of information is estimated to average 15 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC/ATSDR Information Collection Review Office, 1600 Clifton Road NE, MS D- 74, Atlanta, Georgia 30333; ATTN: PRA (0920-0879).’
| File Type | application/vnd.openxmlformats-officedocument.wordprocessingml.document |
| Author | may2 |
| File Modified | 0000-00-00 |
| File Created | 2021-01-31 |